The Use of Radiation Dosimetry to Optimize Radiopharmaceutical Therapy

Presenter: Joseph O'Donoghue, Ph.D. | Attending Physicist, Memorial Sloan-Kettering Cancer Center

Radiopharmaceutical therapies exploit the tumor targeting ability of small molecules, peptides, or antibodies to treat solid cancers with cytotoxic radiation while limiting damage to normal tissues. 

During this webinar, the presenter will discuss:

  • The complexities associated with radiopharmaceutical therapy development and translation into the clinic
  •  The controversial role of dosimetry in clinical radiopharmaceutical therapy
  •  The use of quantitative analysis to optimize radiopharmaceutical therapy

Register Below for On-Demand Access:

ODonoghue 2


Attending Physicist, Memorial Sloan-Kettering Cancer Center

Dr. O'Donoghue is a medical physicist with a long-standing interest in the imaging and treatment of malignant disease by molecular-targeted radionuclides. Dr. O'Donoghue’s work includes radiation dosimetryradiobiological modeling, experimental and clinical nuclear imaging, kinetic analysis and tumor response assessment for radiolabeled antibodies and small molecules. In the lab he has investigated the application of ex-vivo analysis featuring digital autoradiography and immunohistochemistry to examine the microdistribution of targeted radionuclides in patient tumors.